ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,099.96
1.02%
US Tech 100
17,244.00
1.57%
다우존스 지수
38,239.66
0.40%
Bitcoin
63,909.12
0.79%
Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Arbutus Biopharma Corporation (ABUS)

  7. Arbutus Biopharma Corporation (ABUS) 뉴스

ABUS Arbutus Biopharma Corporation

2.73
0.01 (0.37%)
27 4월(4) 2024 - 마감
15분 지연
기업명 주식 심볼 시장 주식 타입
Arbutus Biopharma Corporation ABUS 나스닥 보통주
  가격 변동 가격 변동 % 주식 가격 최근 거래 시간
Upgrade Icon
0.01 0.37% 2.73 13:00:00
개장가 저가 고가 종가 전일 종가
2.73 2.70 2.78 2.73 2.72
시세 정보 더보기 »

최근 뉴스

일자 시간 출처 제목
18/04/202420:30GLOBEArbutus to Report First Quarter 2024 Financial Results and..
04/04/202421:30GLOBEArbutus Biopharma Announces Claim Construction Ruling in its..
08/03/202421:30GLOBEArbutus to Participate in Two Upcoming Investor Conferences
06/03/202406:48EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
29/02/202421:31EDGAR2Form 8-K - Current report
29/02/202421:30GLOBEArbutus Reports Fourth Quarter and Year End 2023 Financial..
15/02/202421:30GLOBEArbutus to Report Fourth Quarter and Year End 2023 Financial..
15/02/202406:38EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
15/02/202400:48EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
06/02/202409:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/02/202409:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/02/202409:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/02/202409:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/01/202421:31EDGAR2Form 8-K - Current report
08/01/202421:30GLOBEArbutus Announces 2024 Corporate Objectives and Provides..
05/01/202406:09EDGAR2Form 8-K - Current report
21/11/202322:00EDGAR2Form SC 13G - Statement of acquisition of beneficial..
10/11/202306:02EDGAR2Form 8-K - Current report
08/11/202321:30GLOBEArbutus to Present at Jefferies London Healthcare Conference
08/11/202306:18EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202321:31EDGAR2Form 8-K - Current report
07/11/202321:30GLOBEArbutus Reports Third Quarter 2023 Financial Results and..
07/11/202321:16EDGAR2Form 8-K - Current report
07/11/202321:15GLOBEArbutus Announces CEO, William Collier, to Retire December..
24/10/202320:30GLOBEArbutus to Report Third Quarter 2023 Financial Results and..
18/10/202320:30GLOBEArbutus to Present at H.C. Wainwright 4th Annual Hepatitis B..
11/10/202321:06EDGAR2Form 8-K - Current report
11/10/202321:05GLOBEArbutus Announces Multiple Abstracts Accepted for..
12/09/202306:07EDGAR2Form SC 13G - Statement of acquisition of beneficial..
12/09/202305:16EDGAR2Form 8-K - Current report
12/09/202305:15GLOBEArbutus Announces Pipeline Updates and Dosing of the First..
07/09/202320:30GLOBEArbutus to Participate in Two Upcoming Investor Conferences
04/08/202305:18EDGAR2Form S-8 - Securities to be offered to employees in employee..
04/08/202305:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/08/202320:31EDGAR2Form 8-K - Current report
03/08/202320:30GLOBEArbutus Reports Second Quarter 2023 Financial Results..
20/07/202320:30GLOBEArbutus to Report Second Quarter 2023 Financial Results and..
14/07/202305:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/07/202305:11EDGAR2Form 3 - Initial statement of beneficial ownership of..
13/07/202305:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/07/202305:48EDGAR2Form 3 - Initial statement of beneficial ownership of..
13/07/202305:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/07/202305:10EDGAR2Form 3 - Initial statement of beneficial ownership of..
12/07/202320:31EDGAR2Form 8-K - Current report
12/07/202320:30GLOBEArbutus Appoints Melissa V. Rewolinski, PhD to its Board of..
11/07/202305:02EDGAR2Form 8-K - Current report
11/07/202305:01GLOBEArbutus Appoints Two New Executives
21/06/202320:30GLOBEArbutus Doses First Patient in Additional Treatment Arm of..
21/06/202315:01GLOBEArbutus Presents Preliminary AB-729 and Pegylated Interferon..
07/06/202315:01GLOBEArbutus to Present AB-729 and AB-836 Data at EASL Congress..

최근 히스토리

NASDAQ
ABUS
Arbutus Biopharma
Delayed Upgrade Clock
ADVFN Logo

대한변국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유